Morbidity, mortality, and long-term consequences associated with diarrhoea from Cryptosporidium infection in children younger than 5 years: a meta-analyses study

Ibrahim A Khalil, Christopher Troeger, Puja C Rao, Brigitte F Blacker, Alexandria Brown, Thomas G Brewer, Danny V Colombara, Eugenio L De Hostos, Cyril Engmann, Richard L Guerrant, Rashidul Haque, Eric R Houp, Gagandeep Kang, Poonum S Korpe, Karen L Katloff, Aldo A M Lima, William A Petri Jr, James A Platts-Mills, David A Shoultz, Mohammed H Forouzanfar, Simon I Hay, Robert C Reiner Jr, Ali H Mokdad

Summary

Background The protozoan Cryptosporidium is a leading cause of diarrhoea morbidity and mortality in children younger than 5 years. However, the true global burden of Cryptosporidium infection in children younger than 5 years might have been underestimated in previous quantifications because it only took account of the acute effects of diarrhoea. We aimed to demonstrate whether there is a causal relation between Cryptosporidium and childhood growth and, if so, to quantify the associated additional burden.

Methods The Global Burden of Diseases, Injuries, and Risk Factors study (GBD) 2016 was a systematic and scientific effort to quantify the morbidity and mortality associated with more than 300 causes of death and disability, including diarrhoea caused by Cryptosporidium infection. We supplemented estimates on the burden of Cryptosporidium in GBD 2016 with findings from a systematic review of published and unpublished cohort studies and a meta-analysis of the effect of childhood diarrhoea caused by Cryptosporidium infection on physical growth.

Findings In 2016, Cryptosporidium infection was the fifth leading diarrhoeal aetiology in children younger than 5 years, and acute infection caused more than 48 000 deaths (95% uncertainty interval [UI] 24 600–81 900) and more than 4·2 million disability-adjusted life-years lost (95% UI 2·2 million–7·2 million). We identified seven data sources from the scientific literature and six individual-level data sources describing the relation between Cryptosporidium and childhood growth. Each episode of diarrhoea caused by Cryptosporidium infection was associated with a decrease in height-for-age Z score (0·049, 95% CI 0·014–0·080), weight-for-age Z score (0·095, 0·055–0·134), and weight-for-height Z score (0·126, 0·057–0·194). We estimated that diarrhoea from Cryptosporidium infection caused an additional 7·85 million disability-adjusted life-years (95% UI 5·42 million–10·11 million) after we accounted for its effect on growth faltering—153% more than that estimated from acute effects alone.

Interpretation Our findings show that the substantial short-term burden of diarrhoea from Cryptosporidium infection on childhood growth and wellbeing is an underestimate of the true burden. Interventions designed to prevent and effectively treat infection in children younger than 5 years will have enormous public health and social development impacts.

Funding The Bill & Melinda Gates Foundation.

Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Cryptosporidium was one of the four major contributors to the Global Enteric Multicenter Study (GEMS), determining the appropriate strategy for intervention. Infection-related consequences is the first step toward world Cryptosporidium from infection. Understanding the large variation in burden estimates for diarrhoea further study.

We present findings from GBD 2016 on the burden of diarrhoeal disease and of undernutrition due to Cryptosporidium between ages 2 years and 49 years old. We expanded upon findings from GBD 2016 on the burden of diarrhoeal disease due to Cryptosporidium with a systematic review and meta-analysis on the effect of Cryptosporidium on physical growth in children younger than 5 years.

Estimation of acute burden of diarrhoeal disease due to Cryptosporidium

Attribution of Cryptosporidium to diarrhoea mortality and morbidity in GBD has been described in detail previously. GBD uses disability-adjusted life-years (DALYs) as a metric of disease burden. DALYs are the sum of years of life lost and years lived with disability. DALYs due to diarrhoea from Cryptosporidium infection, estimated as part of GBD 2016, include diarrhoea episodes and deaths caused by Cryptosporidium. These are referred to from here forward as acute DALYs. The analysis of acute burden uses three separate methodological processes to evaluate the global burden of diarrhoeal diseases; these three processes estimate diarrhoea mortality, diarrhoea dysfunction, a broad intestinal syndrome characterised by local inflammation, nutrient malabsorption, barrier disruption, and bacterial translocation that is thought to be a result of chronic exposure to a variety of enteric pathogens (including protozoans such as Cryptosporidium). Malnutrition might predispose children to infection, but a Cryptosporidium infection could also impede nutrient absorption and thereby cause malnutrition, leading to a longer lasting and vicious cycle of reinfection. The severity and extent of these outcomes warrant further study.

Methods

Overview

We aimed to show whether there is a causal relationship between Cryptosporidium and childhood growth and, if so, to quantify the associated additional burden.

Evidence before this study

In the Global Burden of Disease Study (GBD) 2015, diarrhoea was estimated to have caused 499,000 deaths (95% uncertainty interval 447,000–558,000), and Cryptosporidium was one of the three aetiologies responsible for the most deaths in children younger than 5 years. Cryptosporidium has long been recognised to be associated with long-term sequelae, including linear growth shortfalls (stunting). We searched PubMed on May 24, 2018, with the terms Cryptospor* AND (“stunting” OR “wasting” OR “growth” OR “malnutrition”) AND (“diarrhoea”) AND (“prospective” OR “case control” OR “trial” OR “cohort”), without date or language restrictions and identified 103 publications. Beginning in the mid-1990s, an association between Cryptosporidium infection and childhood growth failure was identified in cohort studies in Brazil, Peru, and Guinea-Bissau. Although these publications suggested the potentially large impact of Cryptosporidium infection on weight and height gain, none of the studies in our search result attempted to synthesise all of the available data on Cryptosporidium infection and childhood growth or attempted to quantify the total burden of Cryptosporidium infection.

Added value to this study

We aimed to show whether there is a causal relationship between Cryptosporidium and childhood growth and to quantify the additional burden associated with non-fatal infection due to poor growth outcomes. Our findings suggest that the previously reported burden of Cryptosporidium infection is underestimated and that Cryptosporidium diarrhoea affects childhood health beyond acute illness by decreasing growth. By properly accounting for these long-term outcomes, we estimated that the burden of Cryptosporidium infection is 2.5 times larger than previously reported.

Implications of all the available evidence

The findings have large implications for global public health leaders. Our work provides valuable insight into the true burden of diarrhoea from Cryptosporidium infection and illuminates the challenges and the potential intervention strategies for addressing the global Cryptosporidium infection burden. Our interpretations highlight important knowledge gaps and research priorities, and we call for renewed efforts from policy makers and research funders to accelerate programmes and interventions that maximise health and long-term outcomes.

Research in context
Diarrhoea mortality was modelled in a Bayesian meta-regression platform that uses a compartmental transition model to relate incidence, prevalence, and mortality. Sources for this model included population representative surveys, scientific literature, health-care utilisation data, and modelled diarrhoea mortality estimates. Finally, diarrhoeal aetiologies, including Cryptosporidium infection, were modelled using a counterfactual approach to estimate a population-attributable fraction (PAF). This method leverages the association between the presence of the aetiology and diarrhoea symptoms as well as the frequency of detection of the aetiology in diarrhoeal stool samples. The burden due to Cryptosporidium was calculated as the product of the Cryptosporidium PAF and estimates of diarrhoea morbidity and mortality.

**Estimation of the effect of Cryptosporidium on physical growth**

We did a systematic review of the scientific literature on the effect of *Cryptosporidium* on physical growth in children younger than 5 years in 2016 in GBD regions.
children younger than 5 years. We searched PubMed on July 26, 2017, with no restriction on publication date, using the search string “cryptospor* AND (stunting[Title/Abstract] OR wasting[Title/Abstract] OR growth[Title/Abstract] OR underweight[Title/Abstract] OR development[Title/Abstract] OR malnutrition[Title/Abstract]) AND Humans[Mesh] NOT (rats or mice)”. We excluded non-human studies. We specifically looked for data describing the change in height or weight either measured in metric units or Z scores. Metric units were converted to height-for-age and weight-for-age Z scores based on the WHO sex-specific growth curves.19 We supplemented the systematic literature review with individual-level data from two case-control and four cohort studies. We did panel-based linear regression models with these data, accounting for an interaction term between Cryptosporidium infection and diarrhoea and adjusting for age (days), days between anthropometric measurements, and the previous anthropometric measurement, where measurements for an individual child are treated as repeated measures.

The metadata for the sources can be found in the appendix (p 8). We did a random effects meta-analysis for change in height-for-age Z scores (HAZ; stunting), weight-for-age Z scores (WAZ; underweight), and weight-for-height Z scores (WHZ; wasting) and stratified the results by diagnostic technique used to detect Cryptosporidium. These meta-analyses were done in Stata version 13 using the metan function with the random effects option specified. These effect sizes represent the relative change in HAZ, WAZ, and WHZ per episode of diarrhoea from Cryptosporidium infection and are used to calculate DALYs attributable to Cryptosporidium. We made no distinction in effect size by age.

Estimation of the burden of undernutrition attributable to Cryptosporidium, according to GBD

We also estimated DALYs due to childhood undernutrition in GBD 2016.21 The method for calculating undernutrition DALYs has two components. The first is the prevalence of stunting, underweight, and wasting, measured by HAZ, WAZ, and WHZ.21 The exposure prevalence of each of these categories are estimated for each country, year, age group, and sex group. The prevalence of underweight and wasting was used in the subsequent analysis of the effect of Cryptosporidium diarrhoea on protein-energy malnutrition.

Undernutrition is a risk factor for diarrhoea, measles, and lower respiratory infections (LRIs) in GBD 2016, based on the statistically significant relative risks from a systematic review.22 Each of these outcomes has a
relative risk given undernutrition status (stunted, underweight, wasted) and the relative risks are adjusted for covariance between undernutrition indicators.22

Estimation of the burden of undernutrition attributable to Cryptosporidium infection
To determine the number of undernutrition-associated DALYs attributable to Cryptosporidium, we calculated the change, at the population level, in mean HAZ, WAZ, and WHZ due to the pathogen for each age group, year, sex, and geography from GBD. This PAF was defined as:

$$\text{PAF} = 1 - \frac{\Delta Z\text{score}}{\\text{Diarrhoea Episodes} \times \text{Proportion}_{\text{Crypto}} \times (1 - \text{RR})}$$

Where diarrhoea episodes was the modelled number of diarrhoea episodes (GBD 2016).18 Proportion$_{\text{Crypto}}$ was the frequency of detection of diarrhoea from Cryptosporidium infection (GBD 2016).19 $\Delta Z$ score was the change in Z score per episode of diarrhoea from Cryptosporidium infection from the meta-analysis, and RR was the relative risk of a given outcome (eg, measles) per Z-score change in malnutrition category (ie, per HAZ, WHZ, or WAZ unit change).22 We did not calculate an undernutrition PAF for children younger than 1 month because neonatal weight is predominantly related to birthweight.

To calculate a final PAF for undernutrition due to diarrhoea from Cryptosporidium infection, we accounted for covariance in WHZ, WAZ, and HAZ. We used the same approach as the risk factor analysis for undernutrition in GBD 2016,21 which was defined by:

$$\text{PAF}_{\text{undernutrition}} = 1 - [(1 - \text{PAF}_{\text{WAZ}}) \times (1 - \text{PAF}_{\text{HAZ}}) \times (1 - \text{PAF}_{\text{WHZ}})]$$

The final calculation was to multiply the PAF by the lower respiratory infection, measles, and diarrhoea DALYs estimates to determine the total number of DALYs from those outcomes attributable to Cryptosporidium diarrhoea.

Estimation of the burden of protein–energy malnutrition attributable to Cryptosporidium infection
Cryptosporidium infection affects weight gain. Protein–energy malnutrition is a burden of disease caused by low weight. To estimate the amount of protein–energy malnutrition that was due to Cryptosporidium infection, we estimated the shift in the weight-for-age and weight-for-height distribution due to diarrhoea from Cryptosporidium infection. This was done by evaluating the percentage difference in the observed WAZ and WHZ distribution. The shift in the mean WAZ and WHZ at the population level was represented by:

$$\text{Shift} = \text{Diarrhoea Episodes} \times \text{Proportion}_{\text{Crypto}} \times \frac{\Delta \text{Zscore}}{\text{Crypto diarrhoea episode}}$$

And the counterfactual prevalence of wasting and underweight was calculated by:

$$\text{Prevalence (Counterfactual)} = \text{Prevalence (GBD 2016 estimate)} + \text{Shift}$$

The prevalence of underweight and wasting was converted to a Z score, and we estimated the percentage change in the cumulative density from a normal distribution compared with the observed prevalence:

$$\text{PAF} = \frac{\text{Prevalence (GBD 2016 estimate)} - \text{Prevalence (GBD 2016 estimate)}}{\text{Prevalence (GBD 2016 estimate)}}$$

PAFs were calculated independently for mild, moderate, and severe undernutrition, age group, geography, sex, and year. Final DALYs due to diarrhoea from Cryptosporidium infection were the PAF multiplied by the number of DALYs caused by protein–energy malnutrition.

Uncertainty was carried through the entire analytical process using 1000 draws of the input parameters and modelled estimates. The point values presented are the mean from the 1000 draws, and the lower and upper uncertainty intervals (UIs) are the 2.5th percentile and 97.5th percentile of the 1000 draws.

Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results
In GBD 2016, Cryptosporidium was the fifth leading cause of diarrhoeal mortality in children younger than 5 years,
causing 48 300 deaths (95% UI 24 600–81 900; table 1). Cryptosporidium caused 57 200 deaths (95% UI 29 800–94 700) in all age groups, and more than 80% of deaths from Cryptosporidium infection were in children younger than 5 years. 23 300 (48%) of Cryptosporidium-related deaths in children younger than 5 years were in Nigeria (n=18 900, 95% UI 9 600–33 400) and in the Democratic Republic of the Congo (n=4 400, 1 700–9 000). We estimated 44·8 million episodes of diarrhoea from Cryptosporidium infection (95% UI 20·0 million–88·7 million) in children younger than 5 years in 2016, and the incidence was 69·7 per 1000 child-years (95% UI 31·1–137·9; table 1). In 2016, acute diarrhoeal morbidity and mortality from Cryptosporidium infection was associated with 4 224 000 DALYs (95% UI 2 160 000–7 163 000) in children younger than 5 years worldwide. The burden of disease varied widely between countries, with the highest burden in the Sahel region of sub-Saharan Africa and in central sub-Saharan Africa (figure 1; table 1). The highest rates of acute Cryptosporidium DALYs were in Chad (62·2 per 1000 child-years, 95% UI 16·1–133·1) and Nigeria (55·3 per 1000 child-years, 28·1–97·8; figure 1; appendix p 19). Cryptosporidium was not a large cause of diarrhoea burden in high-income countries (571 DALYs, 95% UI 98–1550). The number of acute DALYs due to Cryptosporidium infection has decreased significantly between 2006 and 2016 (–42·2%, 95% UI −53% to −28%).

Our systematic review retrieved 598 initial results, 49 of which were included for full-text screening, and seven of which provided data (appendix p 8). From our meta-analysis, we calculated that each episode of diarrhoea from Cryptosporidium infection significantly decreased HAZ, WAZ, and WHZ (table 2, appendix pp 10–12). When we stratified our analyses by diagnostic method used, the magnitude of the point estimates were only marginally different for PCR-based diagnostics than for non-PCR diagnostic methods (0·06 vs 0·04 for HAZ; 0·09 vs 0·10 for WAZ), and all meta-analysis data for WHZ used PCR diagnostics. In a meta-analysis of six studies, Cryptosporidium infection in the absence of diarrhoea was significantly associated with decreased HAZ (0·030, 95% CI 0·014–0·045; appendix p 13), but infection in the absence of diarrhoea was not significantly associated with WAZ or WHZ. The asymptomatic burden of Cryptosporidium was not estimated further.

In GBD 2016, the number of Cryptosporidium DALYs affecting children younger than 5 years increased from 4 224 000 DALYs to 12 868 500 DALYs (95% UI 10 148 100–16 010 100) after accounting for undernutrition-associated DALYs—a 153% increase (95% UI 103–232; table 1). The burden of Cryptosporidium was highest...
in sub-Saharan Africa. The highest total rates of DALYs per 1000 child-years occurred in Chad (217·8 per 1000 child-years, 95% UI 132·2–342·1), the Central African Republic (163·7 per 1000 child-years, 108·8–237·8), and Burkina Faso (127·5 per 1000 child-years, 83·1–179·0; figure 2; appendix p 19). These locations also had high rates of acute Cryptosporidium DALYs. The countries with the highest percentage increase in Cryptosporidium DALYs, after accounting for growth impairment, were Cambodia (18162% increase, 95% UI 3784–46 818), Guatemala (15855% increase, 6272–28 108), and Nepal (11082% increase, 4996 to 20 181; figure 2; appendix p 19). These countries tended to have lower burdens of diarrhoea from Cryptosporidium infection but high undernutrition exposure and burdens of lower respiratory infection. These two factors contribute to a large increase in burden due to undernutrition attributable to diarrhoea from Cryptosporidium infection. The relative number of DALYs increased in every country after accounting for undernutrition-associated DALYs, and although the percentage increase tended to be smallest in high-income, western European countries, DALYs only increased by 70% in Botswana (95% UI 29–161; figure 2; appendix p 19).

The major burden of Cryptosporidium was in children aged 28–364 days (figure 4). After accounting for undernutrition-associated DALYs, Cryptosporidium was found to have caused nearly 250 DALYs per 1000 child-years in children younger than 1 year in sub-Saharan Africa, the super-region with the highest burden. Most of this burden is from the long-term outcomes associated with undernutrition. Undernutrition-associated DALYs were associated with 61–94% of all Cryptosporidium DALYs (figure 5). Health consequences associated with increased wasting and underweight accounted for most of this additional burden, which exceeded 30% in all super-regions except sub-Saharan Africa (figure 5). The fraction of Cryptosporidium DALYs due to protein–energy malnutrition ranged from 3% in north Africa and the Middle East and South Asia to 24% in high-income countries. The acute burden of Cryptosporidium ranged from 6% in central Europe, eastern Europe, and central Asia to 39% in sub-Saharan Africa (figure 5).

Discussion
Our findings show that the previously reported burden of Cryptosporidium was an underestimation of the true burden. Diarrhoea from Cryptosporidium infection affects childhood health beyond acute illness by decreasing growth, particularly weight gain, and increasing the risk of subsequent infectious disease episodes. By properly accounting for some of these long-term outcomes, we estimated that the burden of Cryptosporidium is 2·5 times...
higher than previously reported. Our findings call for renewed efforts to control the burden of *Cryptosporidium*. *Cryptosporidium* was the fifth leading cause of diarrhoeal mortality in children younger than 5 years in 2016. The importance of *Cryptosporidium* as a cause of moderate-to-severe diarrhoea has been identified elsewhere. There are also geographic patterns to the burden of *Cryptosporidium*; the burden appears to be focused in central and western sub-Saharan Africa, which is an area with a high risk of infectious disease. This is also an area of the world with relatively sparse data on the burden of diarrhoea and *Cryptosporidium* aetiology, which should be recognised in the interpretation of our estimates.

There are several reasons for suspecting that diarrhoea and *Cryptosporidium* infection impair physical growth. The rapid fluid loss and inability to absorb macronutrients and micronutrients during a diarrhoeal episode disrupts weight and height gain. Furthermore, chronic or repeated enteric infections are thought to disrupt normal gut function by changing endothelial cells, causing chronic inflammation, and flattening the microvilli, which will decrease the area of absorptive tissue. Invasive, intracellular infections such as those caused by *Cryptosporidium* might be more difficult to clear, causing long-lasting inflammation in the enteric system and disruption of the epithelial cell barrier. Low weight, particularly weight-for-height, is a serious risk factor for infectious diseases. Low weight has immediate, acute negative effects on systematic and mucosal immune system functions. Poor height gain is a long-term negative outcome, and if height growth is not restored by the end of the first 2 years of life, it becomes more difficult to recover later in childhood development. Evidence suggests that the failure to meet genetic growth potential could induce poor health outcomes that are lifelong and possibly intergenerational, including cognitive development, poor educational performance, and increased risk of cardiovascular and metabolic diseases in later life.

These data on the distribution of disease burden attributable to *Cryptosporidium* will allow policy makers and research funders to prioritise programmes and interventions that maximise health and long-term outcomes. Additionally, our work draws attention to important knowledge gaps and research priorities. Considerable uncertainty about the nature of the *Cryptosporidium* burden remains. Even less is known about the long-term consequences of infection, such as the link between cognitive development and the stunting due to *Cryptosporidium* infection. We did not distinguish between acute, persistent, or prolonged diarrhoea, yet evidence suggests that *Cryptosporidium* is associated with an extended duration of diarrhoea and that long-lasting diarrhoea could affect the long-term burden non-linearly. Our findings call for further investigations about the prevalence of asymptomatic infection and how such infections can also lead to morbidity. Although our data suggest that *Cryptosporidium* infection in the absence of diarrhoea might impede linear growth, quantifying the prevalence of asymptomatic infection was beyond the scope of this work. Attention to these limitations could have important implications for which interventions will best address the *Cryptosporidium* burden through prevention and treatment.

In terms of scalable interventions, no vaccine for *Cryptosporidium* exists, and unfortunately, in view of scientific, logistical, and economic challenges, the develop-
ment timeline is expected to be long. Effective anti-parasitic vaccines to prevent infection of human beings and disease have historically been quite challenging to develop. Improved knowledge about how Cryptosporidium behaves within other organisms, increased understanding of the host’s immune response to infection by the parasite, and the annotation of Cryptosporidium genomes essential to fill crucial gaps in our knowledge of how the pathogen behaves. Despite substantial efforts, no antiparasitic vaccine for use in human beings has been licensed to date. For example, the antiparasitic vaccine closest to approval for human use, the RTS,S malaria vaccine candidate, has been in development for more than 30 years. Furthermore, available therapeutic options for cryptosporidiosis hardly exist for most wild-type infections in children living in developing countries. These children, particularly those with immunocompromising conditions such as HIV, are at highest risk of severe disease and long-term sequelae. In 2002, the US Food and Drug Administration approved nitazoxanide for the treatment of Cryptosporidium and Giardia duodenalis infections in children aged 1–11 years. Nitazoxanide might be
38% effective at treating protozoal diarrhoeal infections in immunocompetent people, but it does not appear to be as efficacious in these high-risk populations.\textsuperscript{7,8} In addition to managing dehydration with fluids and oral rehydration solutions, effective therapeutic strategies for Cryptosporidium infection might depend on accurate point-of-care diagnostics. Existing diagnostic tests include microscopy of stool for oocysts, immunofluorescent assay, dipstick ELISA, and PCR, but a rapid, low-tech, sensitive, specific, and affordable diagnostic test that is suitable for low-resource settings is not yet available. Studies have shown that quantitative PCR is more sensitive for detecting Cryptosporidium than traditional laboratory methods,\textsuperscript{9,10} so non-molecular diagnostics might underestimate the true prevalence. The sensitive diagnostic technologies have detected Cryptosporidium in a sizeable percentage (8.5%) of moderate-to-severe diarroha cases. In most of these cases, Cryptosporidium was considered the probable causative or dominant pathogen.\textsuperscript{11}

There are several important limitations to this study. Broadly, data from high-burden areas of the world are scarce. Our study required statistical prediction models that are based on a variety of input data types such as mortality, diarrhoea incidence, Cryptosporidium detection frequency, prevalence of childhood undernutrition, and other infectious disease burden. These models predict estimates even where there are no data, relying on space–time and covariate information. However, every step in our estimation process is documented, input data are publicly available, and uncertainty is propagated through the entire process, per the Guidelines for Accurate and Transparent health Estimates Reporting (GATHER).\textsuperscript{12} Children that have poor growth could be at increased risk of Cryptosporidium infection, and this cyclical association introduces a challenge in isolating the temporal relationship between diarrhoea from Cryptosporidium infection and physical growth. However, where possible, data for this study are of growth after diarrhoea from Cryptosporidium infection. Relatively few data are available for the analysis to quantify the relation between diarrhoea from Cryptosporidium infection and childhood growth indicators. We found a difference in the effect sizes when stratifying by the diagnostic method used and these findings suggest that quantitative molecular diagnostics may improve our understanding of Cryptosporidium diarrhoea on childhood growth. Our results might also depend on the age of infection, suggesting that the effect of diarrhoea from Cryptosporidium infection is higher in children under 1 year than in older children. One further bias might arise from the consistency in the input data. We found some variability in the sources used in the meta-analyses; the IP values from the meta-analyses suggested wide dispersion in the data, a limitation that should be partly accounted for in our use of a random-effects meta-analysis.

We did not examine economic burden and societal costs for Cryptosporidium infection, which is suggested to be substantial and to far outweigh direct treatment costs.\textsuperscript{4,5} Rafferty and colleagues\textsuperscript{6} examined direct and indirect costs associated with symptomatic crypto-spordiosis in infants younger than 12 months in Kenya, Peru, and Bangladesh and estimated that direct costs per Cryptosporidium infection were highest in Kenya (US$59–01), Peru ($23–32), and Bangladesh ($7–62). Our work highlights the acute and long-term effects of infection in children younger than 5 years and illustrates the unequitable distribution of that burden in low-income geographies. Interventions to improve childhood health and wellbeing, such as through improved water and sanitation sources and breastfeeding promotion, and a renewed urgency in the development of Cryptosporidium prevention and treatment options could ensure that all children have an opportunity to grow, thrive, and live healthy lives.

Contributors IAK, CT, and DVC did the analyses for this report. IAK prepared the first draft of the manuscript. CT constructed the figures and tables and prepared the appendix. IAK, MHF, AHM, RCR, BFB, and SIH provided overall guidance. IAK, CT, and BFB finalised the manuscript based on comments from other authors and reviewer feedback. PCR and BFB managed the project. All other authors provided data or developed models for indicators, reviewed results, initiated modelling infrastructure, or reviewed and contributed to the report.

Declaration of interests We declare no competing interests.

Acknowledgments We thank William Petri for providing the data included in this analysis and the NIH (grant AI043596).

References
1. Navin TR, Juranez DD. Cryptosporidiosis: clinical, epidemiologic, and parasitologic review. Rev Infect Dis 1984; 6: 313–22.
2. Kirkpatrick BD, Daniels MM, Jean SS, et al. Cryptosporidium stimulates an inflammatory intestinal response in malnourished Haitian children. J Infect Dis 2002; 186: 94–101.
3. Bouzid M, Hunter PR, Chalmers RM, Tyler KM. Cryptosporidium pathogenicity and virulence. Clin Microbiol Rev 2013; 26: 315–34.
4. Kosek M, Alcantara C, Lima AA, Guerrant RL. Cryptosporidium: an update. Lancet Infect Dis 2001; 1: 262–69.
5. Fayer R, Morgan U, Upton SJ. Epidemiology of Cryptosporidium: transmission, detection and identification. Int J Parasitol 2000; 30: 1305–22.
6. Cama V, Bern C, Roberts J, et al. Cryptosporidium species and subtypes and clinical manifestations in children, Peru. Emerg Infect Dis 2008; 14: 567–74.
7. Mondal D, Haque R, Sack RB, Kirkpatrick BD, Petri WA. Attribution of malnutrition to cause-specific diarrheal illness: evidence from a prospective study of preschool children in Mirpur, Dhaka, Bangladesh. Am J Trop Med Hyg 2009; 80: 826–26.
8. Checkley W, Epstein LD, Gilman RH, Black RE, Cabrera L, Sterling CR. Effects of Cryptosporidium parvum infection in Peruvian children: growth faltering and subsequent catch-up growth. Am J Epidemiol 1998; 148: 497–506.
9. Mellnick R, Andersen M, Ahy P, et al. Cryptosporidium infection in infancy as a cause of malnutrition: a community study from Guinea-Bissau, west Africa. Am J Clin Nutr 1997; 65: 149–52.
10. Moore SR, Lima NL, Soares AM, et al. Prolonged episodes of acute diarrhea reduce growth and increase risk of persistent diarrhea in children. Gastroenterology 2010; 139: 1156–64.
Articles

11 Opintan JA, Newman MJ, Ayeh-Kumi PF, et al. Pediatric diarrhea in southern Ghana: etiology and association with intestinal inflammation and malnutrition. *Am J Trop Med Hyg* 2010; 83: 916–43.

12 Checkley W, White AC, Jagannath D, et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for *Cryptosporidium*. *Lancet Infect Dis* 2015; 15: 85–94.

13 Sarabia-Arce S, Salazar-Lindo E, Gilman RH, Naranjo J, Miranda E. Case-control study of *Cryptosporidium parvum* infection in Peruvian children hospitalized for diarrhea: possible association with malnutrition and nosocomial infection. *Pediatr Infect Dis J* 1990; 9: 627–31.

14 Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and etiology of diarrheal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): prospective, case-control study. *Lancet* 2013; 382: 209–22.

15 GBD 2015 Diarrheal Diseases Collaborators. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrheal diseases: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet Infect Dis* 2017; 17: 909–48.

16 GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017; 390: 1151–210.

17 Foreman KJ, Lozano R, Lopez AD, Murray CJ. Modeling causes of death: an integrated approach using CODEm. *Popul Health Metr* 2012; 10: 1.

18 GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017; 390: 1211–59.

19 WHO. WHO child growth standards: methods and development. 2006 http://www.who.int/childgrowth/standards/technical_report/en/ (accessed July 27, 2017).

20 GBD 2015 DALYs and HALE Collaborators, Arora M, Barber RM, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016; 388: 1603–58.

21 GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017; 390: 1345–422.

22 Olofin I, McDonald CM, Ezzati M, et al. Associations of suboptimal growth with all-cause and cause-specific mortality in children under five years: a pooled analysis of ten prospective studies. *PLoS One* 2013; 8: e64636.

23 Rodriguez I, Cervantes E, Ortiz R. Malnutrition and gastrointestinal and respiratory infections in children: a public health problem. *Int J Environ Res Public Health* 2011; 8: 1174–205.

24 MAL-ED Network Investigators. The MAL-ED study: a multinational and multidisciplinary approach to understand the relationship between enteric pathogens, malnutrition, gut physiology, physical growth, cognitive development, and immune responses in infants and children up to 2 years of age in resource-poor environments. *Clin Infect Dis Off Publ Infect Dis Soc Am* 2014; 59 ([supp] 4): S193–206.

25 Colombara DV, Khalil IA-M, Rao PC, et al. Chronic health consequences of acute enteric infections in the developing world. *Am J Gastroenterol Suppl* 2016; S: 4–11.

26 Weisz AJ, Manary MJ, Stephenson K, et al. Abnormal gut integrity is associated with reduced linear growth in rural Malawian children. *J Pediatr Gastroenterol Nutr* 2012; 55: 747–50.

27 Welsh F, Farmery S, MacLennan K, et al. Gut barrier function in malnourished patients. *Gu* 1998; 42: 396–401.

28 Adams PB, Guerrant RL, Zu S, Fang G, Roche JK. *Cryptosporidium parvum* infection of intestinal epithelium: morphologic and functional studies in an in vitro model. *J Infect Dis* 1994; 169: 170–77.

29 Scrimshaw NS, SanGiovanni JP. Synergism of nutrition, infection, and immunity: an overview. *Am J Clin Nutr* 1997; 66: 4645–4775.

30 Sudfeld CR, McCoy DC, Danae G, et al. Linear growth and child development in low- and middle-income countries: a meta-analysis. *Pediatrics* 2015; 135: e1266–75.

31 Lomtiz B, Soares AM, Moore SR, et al. Early childhood diarrhea predicts impaired school performance. *Pediatr Infect Dis J* 2006; 25: 513–20.

32 DeBoer MD, Lima AAM, Oria RB, et al. Early childhood growth failure and the development of adult disease: do enteric infections and malnutrition increase risk for the metabolic syndrome? *Nut Rev* 2012; 70: 642–53.

33 Ajopruru SS, Kooly B, Venkataramani M, et al. Effect of *Cryptosporidium* and giardial diarrhoea on social maturity, intelligence and physical growth in children in a semi-urban in south India. *Ann Trop Paediatr* 2011; 31: 205–12.

34 Schilling KA, Omore R, Derado G, et al. Factors associated with the duration of moderate-to-severe diarrhea among children in rural western Kenya enrolled in the global enteric multicenter study, 2008–2012. *Am J Trop Med Med Hyg* 2017; 97: 248–58.

35 Mead JR. Challenges and prospects for a *Cryptosporidium* vaccine. *Future Microbial* 2010; 5: 335–37.

36 Hoffman SL, Vekemans J, Richie TL, Duffy PE. The march toward malaria vaccines. *Vaccine* 2015; 33 ([supp] 4): D13–23.

37 Calcada MM, White AC. Treatment of *cryptosporidiosis*: do we know what we think we know? *Curr Opin Infect Dis* 2010; 23: 494–99.

38 Sease CL, Kirpatrick BD. Is nitzoxanide an effective treatment for patients with acquired immune deficiency syndrome-related *cryptosporidiosis*? *Nat Clin Pract Gastroenterol Hepatol* 2007; 4: 136–37.

39 Amadi B, Mwija M, Musuku J, et al. Effect of nitzoxanide on morbidity and mortality in Zambian children with *cryptosporidiosis*: a randomised controlled trial. *Lancet* 2002; 360: 1375–80.

40 Liu J, Platts-Mills JA, Juma J, et al. Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study. *Lancet* 2016; 388: 1291–101.

41 Liu J, Kahie F, Mnzigho J, et al. Development and assessment of molecular diagnostic tests for 35 enteropathogens causing childhood diarrhoea: a multicentre study. *Lancet Infect Dis* 2014; 14: 716–24.

42 Stevens GA, Alkema L, Black RE, et al. Guidelines for accurate and transparent health estimates reporting: the GATHER statement. *Lancet* 2016; 388: e119–21.

43 Corso PS, Kramer MH, Blair KA, Addiss DG, Davis JP, Haddix AC. Cost of illness in the 1993 waterborne *Cryptosporidium* outbreak, Milwaukee, Wisconsin. *Emerg Infect Dis* 2003; 9: 426–31.

44 Collee JA, Stockman LJ, Hicks IA, Harrison LE, Zhou FJ, Beach MJ. Direct healthcare costs of selected diseases primarily or partially transmitted by water. *Epidemiol Infect* 2012; 140: 2003–13.

45 Rafferty ER, Schurer JM, Arndt MB, et al. Pediatric *cryptosporidiosis*: an evaluation of healthcare and societal costs in Peru, Bangladesh and Kenya. *PLoS One* 2017; 12: e018280.